Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Acerus Pharmaceuticals Usa LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is overseen by 1 distinct examiner and is situated in 1 distinct art unit. The company's current prosecution presence is focused on this single matter, which suggests a highly targeted approach to securing patent protection in the biotechnology sector.
The busiest examiner for the portfolio is REYNOLDS, FRED H, who has 1 pending office action. As the company only has 1 pending action, this examiner is the sole point of contact for the current active portfolio. The reliance on 1 distinct examiner means the prosecution strategy does not need to account for varying interpretations of patent law across different individuals at the office.
The involvement of 1 distinct art unit indicates a narrow technical classification for the pending application. With 1 pending office action in this examiner's queue, there is no internal data to compare the examiner's behavior against other matters. Practitioners should tailor their arguments to the specific historical trends of this 1 distinct art unit to maximize the likelihood of a favorable outcome.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18829573 | SAFE DESMOPRESSIN ADMINISTRATION | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18829573 | SAFE DESMOPRESSIN ADMINISTRATION | REYNOLDS, FRED H | 1658 | DP | Non-Final OA | — | Pending | Sep 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAcerus Pharmaceuticals Usa LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fred H Reynolds has the most, with 1 of Acerus Pharmaceuticals Usa LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.